AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14685376 — intervention group
Group type: COMPARATOR
Intervention: Alcohol swab friction (F)
Number of subjects: 133
Study 12959269 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg every 12 h
Number of subjects: 14
Study 12959269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg every 12 h
Number of subjects: 14
Study 12959269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metoprolol and nicardipine
Number of subjects: 14
Study 12959269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2888152 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam (15 or 30 mg)
Number of subjects: 21
Study 2888152 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 or 1.0 mg)
Number of subjects: 21
Study 2888152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31677351 — intervention group
Group type: EXPERIMENTAL
Intervention: Summarizing for a professor/boss
Number of subjects: 279
Study 31677351 — intervention group
Group type: EXPERIMENTAL
Intervention: Summarizing for an acquaintance
Number of subjects: 279
Study 31471690 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games (n=53)
Number of subjects: 106
Study 31471690 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=53)
Number of subjects: 106
Study 27826671 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite mentoring
Number of subjects: 30
Study 27826671 — intervention group
Group type: COMPARATOR
Intervention: Offsite mentoring
Number of subjects: 30
Study 25951630 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Yangyin Yiqi Huoxue Recipe (YYHR)
Number of subjects: 312
Study 25951630 — intervention group
Group type: COMPARATOR
Intervention: Xueshuan Xinmaining (Control)
Number of subjects: 312
Study 24823426 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 500
Study 24823426 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (PtCr-EES)
Number of subjects: 500
Study 22517425 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with gemcitabine and cisplatin
Number of subjects: 11
Study 19744867 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous stripping and phlebectomy
Number of subjects: 60
Study 19744867 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy
Number of subjects: 60
Study 17322150 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg)
Number of subjects: 36
Study 17322150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 15564757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brinzolamide
Number of subjects: 20
Study 11595118 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy chest wall radiotherapy (PMCWRT)
Number of subjects: 0
Study 10223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading of tongue twister with delayed auditory feedback (DAF)
Number of subjects: 0
Study 10223678 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 0
Study 10223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading of tongue twister without DAF
Number of subjects: 0
Study 10223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Spelling of alphabet in reverse order
Number of subjects: 0
Study 10223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading of tongue twister with DAF in second test
Number of subjects: 0
Study 7603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin supplement (1 mg vitamin B12, 1.1 mg folate, 5 mg vitamin B6)
Number of subjects: 285
Study 7603218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 7603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin supplement
Number of subjects: 285
Study 2665884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg i.m. every 3 weeks)
Number of subjects: 39
Study 2665884 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 39
Study 391427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed alternate treatment program involving Adriamycin and L‐PAM and Cytoxan, 5‐Fluorouracil, and Prednisone
Number of subjects: 128
Study 391427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed alternate treatment program
Number of subjects: 128
Study 391427 — intervention group
Group type: COMPARATOR
Intervention: Induction treatment programs (Adriamycin and L‐PAM versus Cytoxan, 5‐Fluorouracil, and Prednisone)
Number of subjects: 128
Study 391427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed alternating treatment group
Number of subjects: 128
Study 391427 — intervention group
Group type: COMPARATOR
Intervention: Both treatment regimens
Number of subjects: 128
Study 31994720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ET-1 infusion (8 ng/kg/min for 20 minutes)
Number of subjects: 14
Study 31994720 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 31149923 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media promotion (SoMe) using Twitter, Facebook, and LinkedIn for 30 days
Number of subjects: 68
Study 31149923 — intervention group
Group type: COMPARATOR
Intervention: No social media promotion (NoSoMe)
Number of subjects: 68
Study 29359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education group
Number of subjects: 90
Study 29359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based education group
Number of subjects: 90
Study 29359166 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 26082203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 240
Study 26082203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Number of subjects: 240
Study 26082203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg
Number of subjects: 240
Study 26082203 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 240
Study 26082203 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesia after rotator cuff repair vs subacromial decompression
Number of subjects: 240
Study 26082203 — intervention group
Group type: EXPERIMENTAL
Intervention: Age effect on postoperative analgesia
Number of subjects: 240
Study 22987897 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education and behaviour management (n = 35)
Number of subjects: 105
Study 22987897 — intervention group
Group type: COMPARATOR
Intervention: Parent education and counselling (n = 35)
Number of subjects: 105
Study 22503223 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST+BWM
Number of subjects: 232
Study 22503223 — intervention group
Group type: COMPARATOR
Intervention: PCST-only
Number of subjects: 232
Study 22503223 — intervention group
Group type: COMPARATOR
Intervention: BWM-only
Number of subjects: 232
Study 22503223 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 232
Study 19301940 — intervention group
Group type: EXPERIMENTAL
Intervention: Klarithran MR (generic formulation of clarithromycin)
Number of subjects: 0
Study 19301940 — intervention group
Group type: COMPARATOR
Intervention: Klacid XL (originator formulation of clarithromycin)
Number of subjects: 0
Study 17709915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily for 3 months
Number of subjects: 66
Study 17709915 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg daily for 3 months
Number of subjects: 66
Study 17709915 — intervention group
Group type: COMPARATOR
Intervention: Control group (36 healthy subjects)
Number of subjects: 66
Study 14634716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31
Study 14634716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11424313 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 28
Study 11424313 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 28
Study 9663813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg
Number of subjects: 11
Study 9663813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg with quinidine 50 mg
Number of subjects: 11
Study 9663813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7828564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative endoscopic surveillance program (compliant group, n=88)
Number of subjects: 212
Study 7828564 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant group (n=124)
Number of subjects: 212
Study 7828564 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic tumor recurrences (both compliant and noncompliant)
Number of subjects: 212
Study 7828564 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic tumor recurrences (both compliant and noncompliant)
Number of subjects: 212
Study 2595270 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate (46 mmol/l) in effervescent glucose-electrolyte solution
Number of subjects: 0
Study 2595270 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (36 mmol/l) in effervescent glucose-electrolyte solution
Number of subjects: 0
Study 2595270 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate-containing oral rehydration solution
Number of subjects: 0
Study 129056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosin
Number of subjects: 56
Study 129056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pectoral nerve block (PECS)
Number of subjects: 38
Study 30396100 — intervention group
Group type: COMPARATOR
Intervention: Erector spinae plane block (ESP)
Number of subjects: 38
Study 29241890 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-directed care using Oncotype DX™
Number of subjects: 0
Study 29241890 — intervention group
Group type: COMPARATOR
Intervention: Standard care (chemotherapy for all)
Number of subjects: 0
Study 26210348 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstainers)
Number of subjects: 380
Study 26210348 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (control group)
Number of subjects: 380
Study 24231479 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 24231479 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 22105586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg)
Number of subjects: 19
Study 22105586 — intervention group
Group type: COMPARATOR
Intervention: Control (no Oseltamivir)
Number of subjects: 19
Study 19175892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 74
Study 19175892 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 74
Study 19175892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 17379291 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 516
Study 17379291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary omega-6 fatty acid restriction
Number of subjects: 516
Study 17379291 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fatty acid exposure (plasma levels, dietary intake, compliance)
Number of subjects: 516
Study 15229773 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of hypertrophied anal papillae or fibrous polyps after sphincterotomy
Number of subjects: 80
Study 15229773 — intervention group
Group type: COMPARATOR
Intervention: Only sphincterotomy
Number of subjects: 80
Study 11453509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) nasal spray, 42 micrograms/spray, administered intranasally twice daily for two weeks.
Number of subjects: 6
Study 11453509 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray (placebo), administered intranasally twice daily for two weeks.
Number of subjects: 6
Study 9462565 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA)
Number of subjects: 1465
Study 9462565 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 1465
Study 9462565 — intervention group
Group type: EXPERIMENTAL
Intervention: Other devices
Number of subjects: 1465
Study 9462565 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone balloon use
Number of subjects: 1465
Study 7846938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Number of subjects: 40
Study 7846938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine and verapamil (1,500 mg + 240 mg/day)
Number of subjects: 40
Study 7846938 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Number of subjects: 40
Study 7846938 — intervention group
Group type: COMPARATOR
Intervention: Quinidine and verapamil (480 mg/day + 240 mg/day)
Number of subjects: 40
Study 7846938 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 40
Study 3276824 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 113
Study 3276824 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 113
Study 3276824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CAFVP followed by surgery or RT)
Number of subjects: 113
Study 31564697 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MMP‐9 levels in patients with PSD (658.8 ng/mL)
Number of subjects: 558
Study 31564697 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest MMP‐9 quartile
Number of subjects: 558
Study 31564697 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 standard deviation increase in log-MMP‐9
Number of subjects: 558
Study 31564697 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐9 added to conventional risk factors model
Number of subjects: 558
Study 30055336 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment delivered by peer coaches over 18 months
Number of subjects: 375
Study 30055336 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment delivered by peer coaches
Number of subjects: 375
Study 30055336 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach intervention
Number of subjects: 375
Study 26977856 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months' self-referral reminder
Number of subjects: 155
Study 24852376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 600 mg twice daily for 5 days
Number of subjects: 624
Study 24852376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 300 mg twice daily for 5 days
Number of subjects: 624
Study 24852376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 22209057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 8
Study 19682359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid reduction with nicotine patches and acute nicotine replacement therapy
Number of subjects: 0
Study 19682359 — intervention group
Group type: COMPARATOR
Intervention: Standard abrupt cessation with nicotine patches only
Number of subjects: 0
Study 17633358 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenshen Huatan Recipe (WHR)
Number of subjects: 60
Study 17633358 — intervention group
Group type: COMPARATOR
Intervention: Conventional and symptomatic treatment (Control)
Number of subjects: 60
Study 14999518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug plus intranasal calcitonin (group 2)
Number of subjects: 27
Study 14999518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug (group 1)
Number of subjects: 27
Study 14999518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 27
Study 14999518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug (group 1) and Antithyroid drug plus intranasal calcitonin (group 2)
Number of subjects: 27
Study 11600827 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-therapy protocol (zidovudine/lamivudine or stavudine/didanosine or stavudine/lamivudine with protease inhibitor)
Number of subjects: 159
Study 11600827 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intensification protocol (ritonavir/saquinavir or ritonavir/saquinavir/stavudine)
Number of subjects: 159
Study 11600827 — intervention group
Group type: COMPARATOR
Intervention: Induction-maintenance protocol (saquinavir/nelfinavir/lamivudine/stavudine)
Number of subjects: 159
Study 11600827 — intervention group
Group type: COMPARATOR
Intervention: Discontinued study medication
Number of subjects: 159
Study 9647139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 0
Study 9647139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 0
Study 9647139 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 9647139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8034817 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and skill building
Number of subjects: 103
Study 8034817 — intervention group
Group type: EXPERIMENTAL
Intervention: Support, skill building, transfer, and parent training procedures
Number of subjects: 103
Study 8034817 — intervention group
Group type: EXPERIMENTAL
Intervention: Support alone
Number of subjects: 103
Study 8034817 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 103
Study 8034817 — intervention group
Group type: COMPARATOR
Intervention: Nonstressed controls (26 children from intact homes)
Number of subjects: 103
Study 3289770 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after pre‐treatment with d‐tubocurarine 0.05 mg.kg‐1
Number of subjects: 60
Study 3289770 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 350 micrograms.kg‐1 after a priming dose of 50 micrograms.kg‐1
Number of subjects: 60
Study 31867653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with <15.8 mg/g nicotine
Number of subjects: 169
Study 31867653 — intervention group
Group type: COMPARATOR
Intervention: Higher nicotine doses (2.4, 5.2, and 15.8 mg/g of tobacco)
Number of subjects: 169
Study 28625852 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge intervention with home monitoring by a skilled nurse in neonatal care.
Number of subjects: 0
Study 28625852 — intervention group
Group type: COMPARATOR
Intervention: Usual care until discharge (Control group).
Number of subjects: 0
Study 26116711 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,800 mg/day for 4 days plus 2,700 mg before the experimental session
Number of subjects: 10
Study 26116711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 23411128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosupernatant plasma (CSP)
Number of subjects: 61
Study 23411128 — intervention group
Group type: COMPARATOR
Intervention: Solvent/detergent plasma (SDP)
Number of subjects: 61
Study 21220730 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 118
Study 21220730 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 118
Study 19455501 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs-based prophylaxis for heterotopic ossification (HO)
Number of subjects: 407
Study 19455501 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of red cells or having general as well as epidural or spinal anaesthesia
Number of subjects: 407
Study 19455501 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 407
Study 19455501 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive surgical bleeding indicators
Number of subjects: 407
Study 17576868 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 149
Study 17576868 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 149
Study 17576868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 14667699 — intervention group
Group type: EXPERIMENTAL
Intervention: Precocious reader
Number of subjects: 0
Study 14667699 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison 11-year-olds
Number of subjects: 0
Study 11069188 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical fractures (hip fractures)
Number of subjects: 6459
Study 11069188 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical fractures (vertebral fractures)
Number of subjects: 6459
Study 11069188 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical fractures (all types)
Number of subjects: 6459
Study 11069188 — intervention group
Group type: COMPARATOR
Intervention: Forearm or other fractures (non-hip, non-wrist, nonvertebral)
Number of subjects: 6459
Study 9049659 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 treatment
Number of subjects: 3
Study 8339634 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP ventilation for 40 minutes
Number of subjects: 11
Study 3011891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian (L-O-V) diet
Number of subjects: 59
Study 3011891 — intervention group
Group type: COMPARATOR
Intervention: Control omnivore diet
Number of subjects: 59
Study 28746788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone regimen (day 1: intravenous dexamethasone [20 mg] and granisetron [3 mg] before TACE; days 2 and 3: intravenous dexamethasone [8 mg])
Number of subjects: 120
Study 28746788 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (day 1: intravenous placebo [saline] and granisetron [3 mg]; days 2 and 3: intravenous placebo)
Number of subjects: 120
Study 27788510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C/E supplementation with CCB/amlodipine
Number of subjects: 0
Study 27788510 — intervention group
Group type: COMPARATOR
Intervention: ARB/olmesartan or CCB/amlodipine
Number of subjects: 0
Study 27788510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C/E supplementation
Number of subjects: 0